1. Swerdlow, SH, Campo, E, Pileri, SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375–2390.
Google Scholar | Crossref | Medline | ISI2. Freedman, A, Jacobsen, E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 2020; 95: 316–327.
Google Scholar | Crossref | Medline3. Teras, LR, Desantis, CE, Cerhan, JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66: 443–459.
Google Scholar | Crossref | Medline4. Carbone, A, Roulland, S, Gloghini, A, et al. Follicular lymphoma. Nat Rev Dis Primers 2019; 5: 83.
Google Scholar | Crossref | Medline5. Okosun, J, Bodor, C, Wang, J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014; 46: 176–181.
Google Scholar | Crossref | Medline6. Czuczman, MS, Grillo-Lopez, AJ, White, CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276.
Google Scholar | Crossref | Medline | ISI7. Junlen, HR, Peterson, S, Kimby, E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia 2015; 29: 668–676.
Google Scholar | Crossref | Medline8. Sarkozy, C, Maurer, MJ, Link, BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol 2019; 37: 144–152.
Google Scholar | Crossref | Medline9. Solal-Celigny, P, Roy, P, Colombat, P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265.
Google Scholar | Crossref | Medline | ISI10. Federico, M, Bellei, M, Marcheselli, L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27: 4555–4562.
Google Scholar | Crossref | Medline | ISI11. Pastore, A, Jurinovic, V, Kridel, R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111–1122.
Google Scholar | Crossref | Medline12. Bachy, E, Maurer, MJ, Habermann, TM, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 2018; 132: 49–58.
Google Scholar | Crossref | Medline13. Casulo, C, Byrtek, M, Dawson, KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 2015; 33: 2516–2522.
Google Scholar | Crossref | Medline | ISI14. Wagner-Johnston, ND, Link, BK, Byrtek, M, et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 2015; 126: 851–857.
Google Scholar | Crossref | Medline15. Zucca, E, Arcaini, L, Buske, C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 17–29.
Google Scholar | Crossref | Medline16. Thieblemont, C, Cascione, L, Conconi, A, et al. A MALT lymphoma prognostic index. Blood 2017; 130: 1409–1417.
Google Scholar | Crossref | Medline17. Montalban, C, Abraira, V, Arcaini, L, et al. Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 2014; 55: 929–931.
Google Scholar | Crossref | Medline18. Conconi, A, Thieblemont, C, Cascione, L, et al. Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment. Haematologica 2020; 105: 2592–2597.
Google Scholar | Crossref | Medline19. Alderuccio, JP, Zhao, W, Desai, A, et al. Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution. J Clin Oncol. Epub ahead of print 12 October 2018. DOI: 10.1200/JCO.18.00138.
Google Scholar | Crossref | Medline20. Luminari, S, Ferrari, A, Manni, M, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol 2018; 36: 689–696.
Google Scholar | Crossref | Medline21. Rummel, MJ, Niederle, N, Maschmeyer, G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–1210.
Google Scholar | Crossref | Medline | ISI22. Flinn, IW, Van Der Jagt, R, Kahl, B, et al. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 2019; 37: 984–991.
Google Scholar | Crossref | Medline23. Marcus, R, Davies, A, Ando, K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017; 377: 1331–1344.
Google Scholar | Crossref | Medline24. Salar, A, Domingo-Domenech, E, Panizo, C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol 2014; 1: e104–e111.
Google Scholar | Crossref | Medline25. Morschhauser, F, Fowler, NH, Feugier, P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018; 379: 934–947.
Google Scholar | Crossref | Medline26. Kiesewetter, B, Willenbacher, E, Willenbacher, W, et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. Blood 2017; 129: 383–385.
Google Scholar | Crossref | Medline27. Link, BK, Day, BM, Zhou, X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol 2019; 184: 660–663.
Google Scholar | Crossref | Medline28. Rivas-Delgado, A, Magnano, L, Moreno-Velazquez, M, et al. Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. Br J Haematol 2019; 184: 753–759.
Google Scholar | Crossref | Medline29. Cheson, BD, Chua, N, Mayer, J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36: 2259–2266.
Google Scholar | Crossref | Medline30. Leonard, JP, Trneny, M, Izutsu, K, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 2019; 37: 1188–1199
Google Scholar | Crossref31. Gopal, AK, Kahl, BS, De Vos, S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008–1018.
Google Scholar | Crossref | Medline | ISI32. Flinn, IW, Miller, CB, Ardeshna, KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019; 37: 912–922.
Google Scholar | Crossref | Medline33. Dreyling, M, Santoro, A, Mollica, L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol 2017; 35: 3898–3905.
Google Scholar | Crossref | Medline34. Zinzani, PL, Samaniego, F, Jurczak, W, et al. Umbralisib, the once daily dual inhibitor of PI3Kδ and casein kinase-1ε demonstrates clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 2 global unity-NHL trial. Blood 2020; 136(Suppl. 1): 34–35.
Google Scholar | Crossref35. Gopal, AK, Schuster, SJ, Fowler, NH, et al. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: results from the open-label, multicenter, phase II DAWN study. J Clin Oncol 2018; 36: 2405–2412.
Google Scholar | Crossref | Medline36. Noy, A, De Vos, S, Coleman, M, et al. Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood Adv 2020; 4: 5773–5784.
Google Scholar | Crossref | Medline37. Morschhauser, F, Tilly, H, Chaidos, A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020; 21: 1433–1442.
Google Scholar | Crossref | Medline38. Panayiotidis, P, Follows, GA, Mollica, L, et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Adv 2021; 5: 823–828.
Google Scholar | Crossref | Medline39. Zinzani, P, Samaniego, F, Jurczak, W, et al. Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: a multicenter, open-label, registration directed phase 2 study. Hematol Oncol 2019; 37(Suppl. 2): 182–183.
Google Scholar | Crossref40. Casulo, C, Friedberg, JW, Ahn, KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 2018; 24: 1163–1171.
Google Scholar | Crossref | Medline41. Jurinovic, V, Metzner, B, Pfreundschuh, M, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German low grade lymphoma study group. Biol Blood Marrow Transplant 2018; 24: 1172–1179.
Google Scholar | Crossref | Medline42. Jimenez-Ubieto, A, Grande, C, Caballero, D, et al. Autologous stem cell transplantation for follicular lymphoma: favorable long-term survival irrespective of pretransplantation rituximab exposure. Biol Blood Marrow Transplant 2017; 23: 1631–1640.
Google Scholar | Crossref | Medline43. Jain, MD, Bachmeier, CA, Phuoc, VH, et al. Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma. Ther Clin Risk Manag 2018; 14: 1007–1017.
Google Scholar | Crossref | Medline44. Locke, FL, Go, WY, Neelapu, SS. Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review. JAMA Oncol 2020; 6: 281–290.
Google Scholar | Crossref | Medline45. Eshhar, Z, Waks, T, Gross, G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993; 90: 720–724.
Google Scholar | Crossref | Medline | ISI46. Till, BG, Jensen, MC, Wang, J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261–2271.